Selective cytotoxicity refers to the ability of a treatment to specifically target cancer cells while sparing normal cells. This is a critical goal in targeted therapy and immunotherapy. For example, monoclonal antibodies like trastuzumab target HER2 receptors on breast cancer cells, minimizing damage to healthy tissue.
